NDT Advance Access published online on December 22, 2004
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh304
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
* To whom correspondence should be addressed.
Personal Opinion
The HEMO Study: applicability and generalizability
2 Veterans Affairs Salt Lake City Health Care System and University of Utah, Salt Lake City, Utah, USA
3 Cleveland Clinic Foundation, Cleveland, Ohio, USA
4 Baylor College of Medicine, Houston, Texas, USA
5 National Institutes of Diabetes, Digestive and Kidney Diseases, Bethesda, Maryland, USA
Michael V. Rocco, E-mail: mrocco{at}wfubmc.edu
This article has no Abstract.
Keywords:
clinical trial; dialysis dose; dialysis flux; haemodialysis; hospitalizations; mortality.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
B. Perrone Dialysis therapy: 'think differently' Nephrol. Dial. Transplant., July 1, 2007; 22(suppl_5): v1 - v2. [Full Text] [PDF] |
||||
